Protagonist Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 6, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 6, 2024

PTGX$135.90+2.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)


· · Three Months Ended · · Six Months Ended
· · June 30, · · June 30,
· 2024 · 2023 · 2024 · 2023
License and collaboration revenue	$4,167	$—	$259,120	$—
Operating expenses:
Research and development	33,520	33,182	67,254	60,598
General and administrative	9,440	9,172	24,350	17,777
Total operating expenses	42,960	42,354	91,604	78,375
Income (loss) from operations	(38,793)	(42,354)	167,516	(78,375)
Interest income	7,404	3,913	11,780	6,404
Other income (expense), net	97	(19)	78	(214)
Income (loss) before income tax (expense) benefit	(31,292)	(38,460)	179,374	(72,185)
Income tax expense (benefit)	676	—	(2,650)	—
Net income (loss)	$(30,616)	$(38,460)	$176,724	$(72,185)
Net income (loss) per share, basic	$(0.50)	$(0.68)	$2.89	$(1.34)
Net income (loss) per share, diluted	$(0.50)	$(0.68)	$2.77	$(1.34)
Weighted-average shares used to compute net income (loss) per share, basic	61,305,289	56,775,742	61,080,489	53,691,965
Weighted-average shares used to compute net income (loss) per share, diluted	61,305,289	56,775,742	63,909,633	53,691,965

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.